Background: Cytoreductive Surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC) is a treatment option with curative intent for selected patients with peritoneal carcinomatosis (PC). The aim of our study was to report our initial experience with CRS and HIPEC performed by a specialized team in a low volume setting. We set out to determine the safety and efficacy of this treatment and also look at our outcomes with respect to perioperative complications and survival.
INTRODUCTION
Peritoneal Carcinomatosis (PC) has generally been regarded to be the terminal stage of cancer progression and carries a very poor prognosis. Population base studies have reported the incidence of synchronous peritoneal metastases to be between 4.3 and 4.8% while metachronous metastases is reported at 4.2% (1, 2) . PC from colorectal origin has been reported to have a median overall survival of 5.2 months (3) . Systemic chemotherapy has been shown to be ineffective because of relative chemoresistance due to lack of tissue penetration in PC (4) . Patients with PC have a poorer prognosis than patients with metastasis to other sites, independent of the chemotherapy regime used for treatment (5) .
The introduction of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitonel
Chemotherpay (HIPEC) to treat PC has provided survival benefits (6) . CRS and HIPEC has become the preferred treatment option for many peritoneal surface malignancies such as peritoneal metastases from colorectal cancer, malignant peritoneal mesothelioma and psuedomyxoma peritonei [PMP] (7). The procedure consists of two phases; a cytoreductive phase with local disease control by macroscopic complete cytoreductive surgery followed by HIPEC to remove microscopic residual disease completely. Five-year survival rates of 19 to 51% have been reported for PC from colorectal origin and 73-86% for PMP treated with CRS and HIPEC (8) (9) (10) .
While this procedure has demonstrated survival benefit, there have been reports of high morbidity, which has prevented its wide acceptance. Two reports have demonstrated acceptable morbidity and mortality at high volume centers however (11, 12) . In the Caribbean there are no high volume academic centers, however similar outcomes have been reported from specialized teams at community hospitals (13).
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SUBJECTS AND METHODS
Between January 2010 and July 2015 we prospectively collected data on all consecutive patients with PC who were treated with CS and HIPEC. A total of seven patients were treated during the study period. The patients were diagnosed with PC from appendix (two) and colorectal (five) origin. PC of appendiceal origin were classified according to Ronnett's system as diffuse peritoneal adenomucinosis (DPAM) or peritoneal mucinous carcinomatosis [PMAC] (14) . Informed consent was obtained from all patients and the ethics committee approved the study.
For all patients, the extent of PC was scored intraoperatively using the peritoneal cancer index (PCI), as described by sugarbaker (15) . Cytoreductive surgery was performed by a single surgeon (WF), with resection of all visible peritoneal deposits and in two cases, simultaneous liver resection was required. The completeness of cytoreduction (CCR) was scored as described by Sugarbaker (15) Demographic, tumor and treatment factors as well as postoperative outcomes were prospectively recorded. Intraoperative parameters such as blood loss, transfusion requirements, length of procedure, number of anastomosis and CCO score were measured.
All complications were recorded prospectively and classified by Dindo-Clavien grade (16) .
Only major complications (grade III, IV or V) were included in the analysis. ICU and overall length of stay were also recorded. Overall survival was calculated from date of surgery to date of death or last follow-up. Progression free survival was recorded from date of surgery to first recurrence. Each recurrence was classified as local, regional or distant.
Statistical analysis
Categorical variables were described in absolute numbers and percentages. The measures of central tendency is reported as the median, mean and ranges as well as standard deviations accompanying the means. Survival analysis was done using the Kaplan-Meier survival method. All analyses were performed using SPSS 21(IBM SPSS Inc, Chicago IL 2013).
RESULTS
Seven patients underwent CRS and HIPEC during the study period. There were 4 males and 3 females; the mean age was 52 years (range 31-71, SD 11.98). There were 5 patients with PC from colorectal origin and 2 from appendix origin but with high grade histology. Median total operating time was 662 minutes (range 360-798, mean: 655.6, SD146). Median estimated blood loss was 1300 (range 100-2000, mean: 1142.9, SD 828) mls. (Table 1) . Four patients required blood transfusions each requiring only 2 units of PRBC.
The median PCI was 13 (range 3-29, mean: 13.1, SD 9.2) and all patients had complete cytoreduction (CCO-0). One (14%) patient had a major complication (grade III).
This patient developed postoperative liver failure, after having a simultaneous right hepatectomy. She had synchronous peritoneal and liver metastasis and had received 12 cycles of Irinotecan base chemotherapy preoperatively. She had a prolonged length of stay but was eventually discharged once her liver function recovered ( Table 2 ). The median length of stay was 14 days (range 10-68, mean: 20.6 SD 21.1) and there were no 30 or 90 day mortality during the study period.
Median follow-up for the group was 19 (range 19-65, mean: 29.7, SD 23.6) months.
Overall mean survival for the group was 43.83 (range 13-65, SD 11.6) months. In the group of patients with PC from colorectal origin, the mean survival was 52 (range 13-65, SD 11.2) months ( Figure) . One patient died in the colorectal group after 13 months because of complications of surgery for a high grade small bowel obstruction, at the time of her death she was disease free.
Mean survival for PC from appendix origin was 20 months. Both patients in the appendix group had high grade histology or PMCA as described by Ronnett(14) . The first patient had a PCI of 29 and subsequently developed a recurrence in the porta hepatis and died after 19 months with widespread disease progression on chemotherapy. The second patient developed a local recurrence in the incision noticed at 6 months follow-up, his CT Pet scan did not show any other evidence of disease, he underwent resection and abdominal wall reconstruction and is now disease free at 16 months follow-up.
DISCUSSION
The combination of CRS and HIPEC is advocated for the management of PC and was first introduced in 1980 by Spratt and colleuages (17) . The procedure has been modified over the years and the technique refined by Dr. Sugarbaker at the Washington Cancer Center and the procedure carries his name (6) . The procedure involves complete tumor removal by means of CRS and HIPEC 6 stripping the peritoneum combined with often complex visceral resections. Heated intraperitoneal chemotherapy is then circulated within the abdomen to sterilize residual mucinous tumor nodules and to avoid entrapment of tumor cells in the early post operative scars.
The obvious benefits of HIPEC are the higher intraabdominal concentration which overcomes the chemoresistance of PC coupled with the decreased systemic levels which reduces the side effects (18) . The penetration of hyperthermic chemotherapeutic agents have been limitied to a few millimeters and therefore the completeness of cytoreduction has prognostic significance and has been shown to be an independent predictor of survival (19) .
CRS and HIPEC morbidity has been reported to be in the range of 12-56% and mortality from 0-12% (11) . High morbidity has been correlated with the extent of carcinomatosis, blood loss, transfusion requirement and number of organs resected (20, 21) .
We present our initial experience with CRS and HIPEC at our center. To the best of our knowledge there are no reports of CRS and HIPEC performed in the Caribbean. The morbidity reported in this series was 14% and there were no 30 day procedure related mortality. This series does represent a highly selected group of patients managed by the same surgeon and anesthetic team in a considerable low resource environment. All patients were seen and managed by a multidisciplinary team before selected to undergo the procedure. (22) . Therefore despite a high rate of complete cytoreduction tumor burden and careful patients' selection remained the most important predictors for prolonged survival.
The limitation of this study is that it is retrospective and a very small population of highly selected patients. The number of patients does reflect the amount of treatable PC in the Bahamas. The incidence of colorectal cancer in the Bahamas is reported as 9.7 per 100,000
and population studies suggest that the burden of PC from colorectal cancer is reported as 4.8 %(1). Therefore we would expect to see approximately 1-2 cases of treatable PC per year in our population of 370,000. One way to increase the experience would be to expand the service to include PC from ovarian origin and to offer the service to the entire Caribbean region.
Careful selection is extremely important in our setting because of the lack of resources and therefore only patients with low volume of disease and good performance status are selected as candidates for the procedure. Careful preoperative evaluation is necessary to determine the extent of PC. This presents a challenge as cross sectional imaging (CT scan) underestimates the extent of disease (23) . The use of laparoscopy prior to laparotomy is a useful tool to better select those patients who may benefit from the procedure, this would warrant further investigation in our setting as it may allow us to better apply limited resources (22) .
CONCLUSION
In summary this review represents our initial experience of CRS and HIPEC in the Bahamas.
We have demonstrated that such complex procedures can be performed safely in a low resource environment by carefully selecting patients and utilizing a specialized team. 
